Workflow
Pfizer(PFE) - 2024 Q2 - Quarterly Results
PFEPfizer(PFE)2024-07-30 12:04

Financial Guidance and Performance - Pfizer raised its full-year 2024 revenue guidance to a range of 59.5to59.5 to 62.5 billion and adjusted diluted EPS guidance to a range of 2.45to2.45 to 2.65[1]. - The company anticipates full-year 2024 operational revenue growth of 9% to 11% compared to 2023, up from the previous estimate of 8% to 10%[9]. - Financial guidance for full-year 2024 anticipates an unfavorable impact of approximately 0.6billiononrevenuesduetochangesinforeignexchangerates[30].−AdjusteddilutedEPSguidanceassumesapproximately5.7billiondilutedweighted−averagesharesoutstanding,withnosharerepurchasesin2024[31].−ThecompanydoesnotprovideguidanceforGAAPReportedfinancialmeasuresotherthanrevenuesduetouncertaintiesinpredictingunusualgainsandlosses[29].RevenueandEarnings−TotalrevenuesforQ22024were0.6 billion on revenues due to changes in foreign exchange rates[30]. - Adjusted diluted EPS guidance assumes approximately 5.7 billion diluted weighted-average shares outstanding, with no share repurchases in 2024[31]. - The company does not provide guidance for GAAP Reported financial measures other than revenues due to uncertainties in predicting unusual gains and losses[29]. Revenue and Earnings - Total revenues for Q2 2024 were 13.283 billion, a 2% increase from 13.007billioninQ22023[37].−Productrevenuesforthefirstsixmonthsof2024decreasedby1413.007 billion in Q2 2023[37]. - Product revenues for the first six months of 2024 decreased by 14% to 23.314 billion compared to 26.988billioninthesameperiodof2023[37].−NetincomeattributabletoPfizerInc.commonshareholdersforQ22024was26.988 billion in the same period of 2023[37]. - Net income attributable to Pfizer Inc. common shareholders for Q2 2024 was 41 million, a 98% decrease from 2.327billioninQ22023[37].−Earningspershare(EPS)forQ22024were2.327 billion in Q2 2023[37]. - Earnings per share (EPS) for Q2 2024 were 0.01, down 99% from 0.41inQ22023[37].−AdjustedincomeforQ22024was0.41 in Q2 2023[37]. - Adjusted income for Q2 2024 was 2.768 billion, with adjusted diluted EPS at 0.60,comparedtoGAAPreportednetincomeof0.60, compared to GAAP reported net income of 41 million[48]. Cost Management and Savings - The company is on track to deliver at least 4billioninnetcostsavingsbytheendof2024fromitscostrealignmentprogram[1].−Pfizerannouncedthelaunchofamulti−yearManufacturingOptimizationProgramaimedatreducingthecostofgoodssold,withexpectedsavingsofapproximately4 billion in net cost savings by the end of 2024 from its cost realignment program[1]. - Pfizer announced the launch of a multi-year Manufacturing Optimization Program aimed at reducing the cost of goods sold, with expected savings of approximately 1.5 billion by the end of 2027[27]. - The one-time costs to achieve the savings from the first phase of the Manufacturing Optimization Program are expected to be around 1.7 billion, primarily recorded in 2024[27]. Research and Development - Pfizer's adjusted R&D expenses for 2024 are projected to be between 11.0 billion and 12.0billion,withafocusondevelopingmedicinesacquiredfromSeagen[10][11].−Pfizerinvested12.0 billion, with a focus on developing medicines acquired from Seagen[10][11]. - Pfizer invested 5.2 billion in internal R&D projects and returned 4.8billiontoshareholdersthroughcashdividendsinthefirsthalfof2024[11].−PositivetoplineresultswerereportedfromthePhase3AFFINEstudyforgiroctocogenefitelparvovec,demonstratingnon−inferiorityandsuperiorityinannualizedbleedingratescomparedtoroutineFactorVIIIprophylaxis[25].−ThePhase3studyforfordadistrogenemovaparvovecdidnotmeetitsprimaryendpointofimprovingmotorfunctioninpatientswithDuchennemusculardystrophy[25].ProductPerformance−Comirnatyrevenuesdeclinedby874.8 billion to shareholders through cash dividends in the first half of 2024[11]. - Positive topline results were reported from the Phase 3 AFFINE study for giroctocogene fitelparvovec, demonstrating non-inferiority and superiority in annualized bleeding rates compared to routine Factor VIII prophylaxis[25]. - The Phase 3 study for fordadistrogene movaparvovec did not meet its primary endpoint of improving motor function in patients with Duchenne muscular dystrophy[25]. Product Performance - Comirnaty revenues declined by 87% operationally to 195 million, while Paxlovid revenues increased by 79% operationally to 251million[1][13].−TheOncologyportfolioshowedstronggrowth,withlegacySeagenproductscontributing251 million[1][13]. - The Oncology portfolio showed strong growth, with legacy Seagen products contributing 845 million in global revenues[1][14]. - The Prevnar family, including Prevnar 20 and Prevnar 13, contributed significantly to revenues, reflecting ongoing demand in both pediatric and adult markets[55]. - Paxlovid generated $251 million in revenue, a significant increase compared to the previous year[53]. Tax and Financial Adjustments - The effective tax rate on adjusted income is expected to be approximately 13.0%, down from 15.0%[10]. - The effective tax rate on Adjusted Income rose to 12.9% in Q2 2024 from 6.8% in Q2 2023, influenced by the non-recurrence of tax benefits from previous years[19]. - The effective tax rate for continuing operations was 130.2% in Q2 2024, up from 3.1% in Q2 2023, primarily due to the nonrecurrence of tax benefits from previous global income tax resolutions[43]. Leadership and Strategic Changes - Pfizer is in the process of identifying a successor for Dr. Mikael Dolsten, who will depart after a 15+ year career, while continuing to assist in the transition[26]. - Andrew Baum, M.D., has been appointed as Chief Strategy and Innovation Officer, effective June 3, 2024, to oversee Pfizer's long-term corporate strategic plan[26]. Market and Competitive Landscape - The company anticipates an immaterial impact in fiscal-year 2024 from recent and expected generic and biosimilar competition for certain products[30]. - Pfizer faces risks from competition, supply chain disruptions, and regulatory changes that could affect pricing and access to its products[59]. - The company anticipates ongoing impacts from COVID-19 on its business, particularly regarding the demand for Comirnaty and Paxlovid, which may lead to reduced revenues and inventory write-offs[58].